DIRS.INFO The most relevant business & tech news

☆ CVS, UnitedHealth say FTC should take Lina Khan and two commissioners off drug middlemen case
▼ + stars: | 2024-10-09 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

CVS Health and UnitedHealth Group are demanding Federal Trade Commission Chairwoman Lina Khan and two other commissioners recuse themselves from a lawsuit accusing the companies and other drug middlemen of boosting their profits while inflating insulin costs for Americans. In separate motions filed Tuesday night with the FTC, CVS and UnitedHealth argued that all three commissioners have an extensive track record of making public statements that indicate "serious bias" against the companies' so-called pharmacy benefit managers. CVS said those statements demonstrate that the commissioners have "prejudged this matter," so their participation in the case "violates due process." The FTC filed the suit last month against the three largest PBMs, CVS Health's Caremark, UnitedHealth Group 's Optum Rx and Cigna 's Express Scripts. The FTC has been investigating PBMs and their role in insulin prices since 2022.

Persons: Lina Khan, UnitedHealth, Khan, Alvaro Bedoya, Rebecca Kelly Slaughter, PBMs Organizations: Financial Services, General Government, Federal Trade Commission, CVS Health, UnitedHealth, Federal Trade, CVS, Amazon, FTC, Zinc Health Services, GPO, Emisar Pharma, OptumRx Locations: Rayburn, U.S, Caremark

☆ Supreme Court rejects Martin Shkreli fine appeal
▼ + stars: | 2024-10-07 | by ( Dan Mangan | ) www.cnbc.com time to read: +3 min

The Supreme Court in rejecting that request did not explain its reason for doing so. Shkreli's request that the Supreme Court take his appeal of federal court decision was his last chance to overturn the penalty related to the drug Daraprim . People pass outside the U.S. Supreme Court on October 7, 2024 in Washington, DC. Shkreli in June asked the Supreme Court to hear his appeal of that ruling, but only as it applied to the financial penalty. The attorney said that the Supreme Court should hear Shkreli's appeal to resolve the so-called circuit split on the question of a defendant's financial liability.

Persons: Martin Shkreli, Benjamin Brafman, Shkreli, pharma bro, Shkreli's Organizations: U.S, CNBC, Federal Trade Commission, pharma, Supreme, Vyera Pharmaceuticals, FTC, Circuit, Appeals Locations: Brooklyn, New York City, U.S, Washington ,, Manhattan, Shkreli, disgorgement

☆ Activist investor Starboard has just informed Pfizer it has taken a significant stake
▼ + stars: | 2024-10-07 | by ( Alex Morrell | ) www.businessinsider.com time to read: +1 min

Starboard Value has taken a significant stake in Pfizer, said people familiar with the matter. Starboard has recently taken positions in Starbucks and Match. The activist investor has informed Pfizer that it has taken a significant stake in the drugmaker, people familiar with the matter told Business Insider. The Wall Street Journal earlier reported the Starboard stake. It also has a stake in Rupert Murdoch's News Corp and has pushed for a breakup of the media conglomerate.

Persons: — Organizations: Pfizer, Service, pharma, Street, Rupert Murdoch's News Corp

☆ Earnings season kicks off after a blowout jobs report upended investors' hopes of another interest-rate cut
▼ + stars: | 2024-10-07 | by ( Dan Defrancesco | ) www.businessinsider.com time to read: +7 min

Tech: Amazon's Prime Day kicks off tomorrow, and there are some deals on surprising items . Amazon's Prime Day kicks off tomorrow, and there are some deals on . Getty Images; Jenny Chang-RodriguezWe've already got one indication companies are in good shape: Friday's blockbuster jobs report . But another blowout report — 250,000 jobs added and at least 4% wage growth — could lead the Fed to reconsider its easing policy. In addition to the usual Prime Day gadgets, like TVs and Airpods, Amazon is dishing out deals on tents, pocket knives, and chainsaws.

Persons: —, Jenny Chang, Rodriguez, Matthew Fox, we'll, Rodriguez We've, there's, Philipp Carlsson, Chelsea Jia Feng, haven't, Donald Trump's, Tyler Le, John Tomac, that's, boomers, They're, Gen Xers, Gen Zers, Kamala Harris, Dan DeFrancesco, Jordan Parker Erb, Hallam Bullock, Grace Lett, Amanda Yen, Milan Sehmbi Organizations: Business, Service, . Tech, Amazon's, Pfizer, Wall Street, JPMorgan, Wells Fargo, Big Tech, Getty, Fed, Boston Consulting, Trump Media, Microsoft, BI, pharma, CBS, ASEAN Locations: Israel, fintech, Vientiane, Laos, New York, London, Chicago

☆ R. Kelly: Supreme Court rejects appeal of federal sex crimes conviction
▼ + stars: | 2024-10-07 | by ( John Fritze | ) edition.cnn.com time to read: +2 min

CNN —The Supreme Court declined on Monday to hear an appeal from R. Kelly, who is currently serving a prison sentence for federal sex crime convictions. Kelly told the Supreme Court that he was wrongly retroactively prosecuted under a federal law that passed in 2003 and made the statute of limitations indefinite for sex crimes with minors. ‘Pharma Bro’ appeal also rejectedIn another case involving a prominent criminal defendant, the Supreme Court declined an appeal Monday from “Pharma Bro” Martin Shkreli, who was fighting a $64 million court-imposed penalty for inflating the price of life-saving medications. Shkreli asked the Supreme Court to review an appeals court decision from earlier this year that upheld the penalty. The Supreme Court denied both appeals on Monday without explaining its reasoning and there were no noted dissents.

Persons: Kelly, Robert Sylvester Kelly, Pharma Bro ’, “ Pharma Bro ” Martin Shkreli, Bro ”, Shkreli, “, CNN’s Elizabeth Wagmeister Organizations: CNN, Pharma, “ Pharma, Turing Pharmaceuticals, “, Supreme Locations: New York, Chicago, America

☆ Cheap stocks to buy in the fourth quarter, according to HSBC
▼ + stars: | 2024-10-05 | by ( Sean Conlon | ) www.cnbc.com time to read: +3 min

It's officially a new trading month, and HSBC recommends investors broaden their exposure in the fourth quarter by seeking out stocks with more reasonable valuations. "These 'big' companies represent the lion's share of equity index returns year to date." HSBC has a buy rating on the stock. In all, 16 of the 29 analysts covering GM have a strong buy or buy rating, and its average price target of $54.35 implies nearly 19% upside from Friday's close, per LSEG. The remaining 11 have a buy or strong buy rating.

Persons: It's, Nicole Inui, General Motors, Goldman Sachs, Goldman Organizations: HSBC, Dow, Industrial, Nasdaq, Federal Reserve, General, GM, Pharmaceutical, Pfizer, Delta Air Lines Locations: Americas, U.S

☆ Beyond Novo: Fund manager likes this under-the-radar pharma stock with a weight loss drug in the works
▼ + stars: | 2024-10-04 | by ( Amala Balakrishner | In Amala-Balakrishner | ) www.cnbc.com time to read: +3 min

"Maybe that weight loss product (by United Laboratories) works, maybe it doesn't. United Laboratories' price-to-earnings of 5.8 times is a fraction of the 34.3 times that Novo Nordisk is trading at, Peche added. [United Laboratories] is making smooth progress in R & D and targets to launch Liraglutide in 2024. Their comments follow United Laboratories' "faster than expected earnings" growth in the first half of the year. Analysts' average price target on United Laboratories is 12.95 Hong Kong dollars, giving it 28.2% potential upside.

Persons: Sean Peche, it's, Peche, there's, that's, Eli Lilly, Amgen, Carol Dou, Sunny Chen, UOB Kay Hian, bode Organizations: Novo Nordisk, Ranmore Fund Management, United Laboratories, Pfizer, AstraZeneca, Global Equity Fund, Hong, Hong Kong bourse, HK Locations: Hong Kong, Novo, Europe, U.S

☆ These are the most important stocks in the U.S., according to Bank of America
▼ + stars: | 2024-10-04 | by ( Pia Singh | In | ) www.cnbc.com time to read: +3 min

There are several key stocks in the U.S. investors need to be mindful of when navigating the current market environment, according to Bank of America. To capture the momentum from this rally, Bank of America screened for the most important stocks in each region of the world — including the U.S. — that have the potential to have the largest impact on portfolio performance, positive or negative. Bank of America found these stocks to be among the most important in the U.S.: Chipmaker Nvidia and oil and gas giant Exxon Mobil ranked fairly high on the firm's steady compounders list within the screen. Meta's shares are up nearly 64% year to date. Other stocks considered the most important names in the U.S. include rideshare company Uber and pharma name Eli Lilly .

Persons: Nigel Tupper, Vivek Arya's, Metaverse, Justin Post, Eli Lilly Organizations: Bank of America, Investment, U.S, Nvidia, Exxon Mobil, Exxon, Meta, Bank of America's, Uber Locations: U.S, Lebanon, Thursday's

☆ This pharma stock is set to surge 71% thanks to autoimmune disease treatment
▼ + stars: | 2024-10-03 | by ( Brian Evans | ) www.cnbc.com time to read: +1 min

Oppenheimer thinks a key treatment for a range of autoimmune diseases can be a growth catalyst for Dianthus Therapeutics stock. The firm initiated coverage of the clinical stage biotechnology company with an outperform rating and a $48 per share price target in a Wednesday note. DNTH YTD mountain Dianthus Therapeutics stock. He estimates a more than $20 billion market for this treatment. Investors will be able to gain insight into the treatment's effectiveness in clinical data that will begin to be released in mid-2025, Allred said.

Persons: Oppenheimer, Trevor Allred, Allred, DNTH103 Organizations: Dianthus Therapeutics, Therapeutics, pharma

☆ UTI International: We see a great future for Indian pharma
▼ + stars: | 2024-10-03 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailUTI International: We see a great future for Indian pharmaPraveen Jagwani, CEO of UTI International, discusses the rise of Indian pharma in the wake of the U.S. Biosecure Act dampening competition from China.

Organizations: Indian pharma, Jagwani, UTI Locations: China

☆ Weight-loss drugs are life-changing — and expensive. Here's one woman's solution.
▼ + stars: | 2024-09-26 | by ( ) www.businessinsider.com time to read: +7 min

A woman who had life-changing results on a popular weight loss drug struggled to afford it for years. AdvertisementTara Rothenhoefer, a 49-year-old Florida resident, says her life changed when she joined a clinical trial for a promising new weight-loss medication. While regulated, these compounded drugs aren't FDA-approved, raising concerns from doctors about variations in quality. The grey market of weight-loss drugs is vast and complicated. In August, Eli Lilly halved the price of its weight-loss drug Zepbound through single-dose vials — a bid to lure customers back to brand-name drugs, analysts said.

Persons: —, Tara Rothenhoefer, Rothenhoefer, Eli Lilly, She's Organizations: Service, Novo Nordisk's, Research, FDA, Pharmaceutical Locations: Florida

☆ Sean ‘Diddy’ Combs wants to testify at his trial, lawyer says: ‘I don’t know that I can keep him off the stand’
▼ + stars: | 2024-09-26 | by ( Elizabeth Wagmeister | ) edition.cnn.com time to read: +4 min

CNN —Sean “Diddy” Combs wants to testify at his criminal trial for charges of sex trafficking and racketeering, according to his attorney. He is very eager to tell his story,” the embattled rap mogul’s attorney Marc Agnifilo said in an interview for a new TMZ documentary. When contacted by CNN, a representative for Combs declined to elaborate on Agnifilo’s comments or say whether Combs will, in fact, take the stand. Asked by TMZ about video of Combs, Agnifilo said that if Combs testifies, he would explain his actions in the video. And I’m not really sure what the baby oil has to do with anything,” Agnifilo said in his interview with TMZ.

Persons: Sean “ Diddy ” Combs, “, Marc Agnifilo, Combs, Cassie Ventura, Agnifilo, ” Agnifilo, Combs “, ”, Agnifilio, Kaitlan Collins, ” Combs, R, Kelly, “ Pharma Bro ” Martin Shkreli, Ghislaine Maxwell, Sam Bankman, Juan Orlando Hernandez Organizations: CNN, TMZ, Prosecutors, ” Prosecutors, Southern, of, Costco, Metropolitan Detention, “ Pharma, MDC Locations: Los Angeles, of New York, New York, Honduras

☆ Brett Favre reveals he's been diagnosed with Parkinson's disease
▼ + stars: | 2024-09-24 | by ( Geoff Weiss | ) www.businessinsider.com time to read: +1 min

Brett Favre said he's recently been diagnosed with Parkinson's disease. Prevacus and its investors, including Favre, have been tied up in a Mississippi welfare fraud case. Go to newsletter preferences Thanks for signing up! AdvertisementFormer NFL star quarterback Brett Favre revealed during a congressional hearing on Tuesday that he had "recently been diagnosed with Parkinson's" — a neurodegenerative disease. "I'm sure you'll understand, while it's too late for me because I've recently been diagnosed with Parkinson's, this is also a cause dear to my heart."

Persons: Brett Favre, he's, Favre, —, it's, I've Organizations: pharma, Service, NFL, Business Locations: Mississippi

Wegovy, the blockbuster weight loss treatment from Novo Nordisk , tops the list of drugs that could soon become part of the second round of price negotiations between manufacturers and Medicare. The Biden administration last month announced new negotiated prices for the first 10 Medicare Part D drugs selected for the talks. He also pushed back on Medicare price negotiations when asked about the potential selection of Wegovy and Ozempic, calling the talks "price-setting" that will have negative consequences for drug innovation. Medicare Part D doesn't cover weight loss treatments unless they are approved and prescribed for another health condition. We'll be following the next round of Medicare drug price negotiations closely, so stay tuned for our coverage.

Persons: Wegovy, Hollie Adams, Biden, it's, Novo, Lars Fruergaard Jørgensen, Lars Jorgensen, Ozempic, Piroschka Van De Wouw, Jørgensen, Semaglutide, We'll, Annika, annikakim.constantino Organizations: Novo Nordisk, Reuters, Specialty Pharmacy, Centers, Medicare, Medicaid Services, Health, Education, Labor, Capitol, CMS, Wall Street, GSK, Astellas Pharma, Epic Systems Locations: London, Britain, Novo, Washington , U.S

☆ ‘Greed, greed, greed’: Sanders demands Ozempic maker lower prices
▼ + stars: | 2024-09-24 | by ( Meg Tirrell | Tami Luhby | ) edition.cnn.com time to read: +7 min

“We are very committed to making sure that Americans have access at an affordable price point for our medicines,” Jorgensen replied. Similarly, Wegovy’s list price is $1,349 in the US, but it costs $186 in Denmark, $140 in Germany and $92 in the United Kingdom, he said. Tuesday’s hearing boiled down to a familiar argument over who is responsible for the US’s higher prices: drug companies that set starting – or “list” – prices or pharmacy benefit managers, the middlemen that negotiate discounts on those list prices in exchange for favorable insurance coverage and access. Jorgensen said Novo Nordisk pays back about 75% of its medicine sales in rebates, discounts and fees, so the net price it receives is far lower than the list price. “The broad totality is that less patients have access to our medicines when we lowered the price,” Jorgensen told Sen. Maggie Hassan, D-New Hampshire, after she pressed him to reduce list prices.

Persons: Sen, Bernie Sanders, ” Sanders, Lars Fruergaard Jorgensen, ” Jorgensen, “, Sanders, Jorgensen, it’s, Maggie Hassan, drugmakers, ”, PBMs, scot, ” Sen, Tim Kaine, Roger Marshall, Eli Lilly, Dr, Sanjay Gupta, Tammy Baldwin Organizations: CNN, Nordisk’s, US, Health, Education, Labor, Pensions, Yale, Novo Nordisk’s Ozempic, Novo Nordisk, Pharmaceutical Care Management Association, Nordisk, Novo Nordisk’s, Federal Trade Commission, CVS, Cigna’s, Republican, Wegovy’s, CNN Health, Medicare, Services Locations: United States, Danish, America, Canada, Denmark, Germany, United Kingdom, New Hampshire, Big, Virginia, Kansas, Novo, Wisconsin

☆ Stocks making the biggest moves midday: Micron, Tesla, Ulta, Intel and more
▼ + stars: | 2024-09-23 | by ( Pia Singh | In | ) www.cnbc.com time to read: +2 min

Check out the companies making headlines in midday trading: Micron Technology — Micron edged 2.7% higher after JPMorgan reiterated the stock as overweight ahead of the memory chipmaker's earnings, which are expected Wednesday after market close. Monday's gain put the stock on track for its biggest advance since Aug. 28, when it popped 9%. Ulta — The cosmetics stock lost more than 3% after a downgrade to hold from buy at TD Cowen. Biohaven — Shares surged 12% after the clinical-stage pharma company announced positive trial data for its drug treating spinocerebellar ataxia known as troriluzole. Intel — Shares of the struggling chipmaker climbed 2.4% after Bloomberg News reported on Sunday that Apollo Global Management proposed to make a multibillion-dollar investment in Intel.

Persons: Harlan Sur, General Motors, Bernstein, Cowen, troriluzole, Ciena, Jesse Pound, Alex Harring, Samantha Subin, Sean Conlon Organizations: Micron Technology, Micron, JPMorgan, Tesla, Barclays, U.S . Army, General, pharma, Intel —, Bloomberg, Apollo Global Management, Intel, CNBC, Qualcomm, Citi

The Federal Trade Commission said Friday that it is suing three drug middlemen, accusing them of inflating insulin prices. PBMs work with insurance companies to negotiate discounted prices from drug companies in exchange for including the drugs in their coverage. The drug was priced at $274 in 2017, as a result of the PBMs rebate system strategy, the FTC said. In July, Democratic and Republican lawmakers blamed executives from Caremark, Express Scripts and Optum Rx for sky-high prescription drug prices in the U.S. during an oversight committee hearing. The lawsuit also comes as states — most recently Vermont — have sued PBMs, alleging they drive up drug costs.

Persons: Cigna, Eli Lilly, Rahul Rao, It’s, Raja Krishnamoorthi, PBMs Organizations: Federal Trade Commission, FTC, CVS, Cigna's, Zinc Health, Ascent Health, Emisar Pharma Services, UnitedHealth, CVS Health, Novo Nordisk, Democratic, Republican, Caremark, New York Times, Republicans, ” Rep Locations: U.S, FTC’s, Vermont

☆ J&J subsidiary files for bankruptcy to advance $8 billion talc settlement
▼ + stars: | 2024-09-20 | by ( ) edition.cnn.com time to read: +3 min

J&J’s Red River Talc unit made its filing in the U.S. Bankruptcy Court for the Southern District of Texas. J&J faces lawsuits from more than 62,000 claimants who alleged that its baby powder and other talc products were contaminated with asbestos and caused ovarian and other cancers. After being rebuffed twice by federal courts, New Brunswick New Jersey-based J&J is attempting again to end the litigation in a so-called “Texas two-step” bankruptcy. J&J said the Red River unit filed the bankruptcy case after it received support of about 83% of current claimants for the proposed bankruptcy plan. The goal is to use the proceeding to force all plaintiffs into one settlement, without requiring J&J itself to file for bankruptcy.

Persons: Reuters —, Johnson, J, Dietrich Knauth, Leigh Jones, Will Dunham, Sandra Maler, Shounak Dasgupta Organizations: Reuters, Johnson, Bankruptcy, Southern, Southern District of, Supreme, Purdue Locations: U.S, Southern District, Southern District of Texas, New Brunswick New Jersey, Texas, Bengaluru

☆ Pfizer is a bottoming stock that will pay you to wait for the comeback, says Carter Worth
▼ + stars: | 2024-09-20 | by ( Carter Braxton Worth | ) www.cnbc.com time to read: +2 min

Former pharmaceutical champion Pfizer (PFE) , down 52% from its December 2021 all-time high, is judged to be in the throes of a "bearish-to-bullish" Reversal. Pfizer, the laggard the past year: Is now... Pfizer, the leader the past month: By our work, PFE represents a compelling "value play". And with a 5.73% dividend yield, one "gets paid" to wait as the stock continues to bottom. THIS CONTENT IS PROVIDED FOR INFORMATIONAL PURPOSES ONLY AND DOES NOT CONSITUTE FINANCIAL, INVESTMENT, TAX OR LEGAL ADVICE OR A RECOMMENDATION TO BUY ANY SECURITY OR OTHER FINANCIAL ASSET. BEFORE MAKING ANY FINANCIAL DECISIONS, YOU SHOULD STRONGLY CONSIDER SEEKING ADVICE FROM YOUR OWN FINANCIAL OR INVESTMENT ADVISOR.

Persons: Carter Braxton Worth Organizations: Pfizer, pharma, Pharmaceuticals Industry Group, CNBC, NBC UNIVERSAL

☆ Morgan Stanley says this pharma stock can rally more than 60% thanks to its narcolepsy treatment
▼ + stars: | 2024-09-20 | by ( Pia Singh | In | ) www.cnbc.com time to read: +2 min

Centessa Pharmaceuticals could be at the forefront of a leading narcolepsy treatment that can send its shares soaring, according to Morgan Stanley. One of the company's drugs is ORX750 for the treatment of sleep-wake disorders, including narcolepsy type 1 and 2, or NT1 and NT2. Additionally, Centessa is developing ORX142 for the treatment of excessive daytime sleepiness, or EDS, in certain neurological, neurodegenerative and psychiatric disorders. The drug is designed to increase wakefulness, reduce cataplexy and potentially be a novel treatment for narcolepsy type 1. Given the firm's view of ORX750 as a now de-risked mechanism for treating narcolepsy, Hung modeled a higher peak market share for the treatment in NT1 by 2036.

Persons: Morgan Stanley, Jeffrey Hung, narcolepsy, Hung Organizations: Pharmaceuticals, IH, EDS Locations: NT1, NT2

☆ Mansion to misery: A glimpse inside the prison Sean ‘Diddy’ Combs now calls home
▼ + stars: | 2024-09-19 | by ( Artemis Moshtaghian | ) edition.cnn.com time to read: +5 min

CNN —Described as “disgusting” with “horrifying” conditions, the detention center music mogul Sean “Diddy” Combs now calls home is a far cry from the Miami and Los Angeles mansions he once lived in. A federal judge denied Combs bail Wednesday saying the bail proposal set forth by his defense attorneys was “insufficient” in addressing the court’s concerns. This after the Federal Bureau of Prisons shuttered its Manhattan complex shortly after multimillionaire financier and accused sex trafficker Jeffrey Epstein died by suicide in 2019. A month later, inmate Edwin Cordero died in a fight that broke out inside the prison. The incident prompted a Justice Department investigation assessing whether the Bureau of Prisons had “adequate contingency plans” to address inmate living conditions.

Persons: Sean “ Diddy ” Combs, he’s, ” Michael Cohen, Donald Trump, Cohen, R, Kelly, “, “ Pharma Bro ” Martin Shkreli, Ghislaine Maxwell, Sam Bankman, Ismael “ El, Ismael “ El Mayo ” Zambada Garcia, Combs, Judge Andrew Carter, Jeffrey Epstein, Emery Nelson, ” Nelson, ” Combs, Marc Agnifilo, “ He’s, ” Cohen, Combs ’, Uriel Whyte, Edwin Cordero Organizations: CNN, Miami, Metropolitan Detention Center, “ Pharma, Wap, Ismael “ El Mayo ”, Federal Bureau of Prisons, MDC, of Prisons, Urgent, MDC Brooklyn, Housing Unit, Prisons, New York Times, Department Locations: Los Angeles, “, New York, Brooklyn, Manhattan, New York City, M.D.C . Brooklyn

☆ Here are Tuesday's biggest analyst calls: Nvidia, Palantir, Amazon, Shopify, Walmart, Microsoft, Palantir, Tesla & more
▼ + stars: | 2024-09-17 | by ( Michael Bloom | ) www.cnbc.com time to read: +7 min

Bank of America reiterates Amazon as buy Bank of America said it's sticking with its buy rating on Amazon following CEO Andy Jassy's letter to employees on Monday. Bank of America adds Palantir to the US1 list Bank of America added the stock to its top picks list. Bank of America reinstates Carvana as buy Bank of America resumed coverage of Carvana and upgraded it to buy saying it sees accelerating growth. Bank of America upgrades Hewlett Packard Enterprise to buy from neutral Bank of America said shares of the company are "attractive." Bank of America upgrades GE Vernova to buy from neutral Bank of America said it sees a "power surge" for the stock.

Persons: Oppenheimer, Andy Jassy's, Andy Jassy, Bernstein, Tesla, underperform Bernstein, Redburn, LSCC, Ford Tamer, Mizuho, DELL, Morgan Stanley, Virgin, Jefferies, it's bullish, JEF, ARMK, Baird, BTIG, " Jefferies, SolarEdge Organizations: Nvidia, " Bank of America, Bank of America, Semiconductor, Stifel, Board, Dell, JPMorgan, ViaSat, United Airlines, Viasat, IFC, Virgin Galactic, Virgin, Citi, UBS, APP, RBC, Baird Conference, Burger, Walmart, Technologies, Healthcare, Barclays, D, WEC, Hewlett Packard Enterprise, of America, Hewlett, Packard Enterprise, GE, Gas Power Services Locations: Europe

☆ GLP-1 pills are coming, and they could revolutionize weight-loss treatment
▼ + stars: | 2024-09-17 | by ( Meg Tirrell | ) edition.cnn.com time to read: +7 min

CNN —Jared Holz thought about taking one of the new GLP-1 drugs for weight loss for months before he actually filled the prescription. At least a dozen similar experimental weight-loss drugs designed to be taken as pills are working their way through clinical trials, with the most advanced now in the third and final stage of testing. Dushay cited hopes that pill versions of GLP-1 drugs could ease shortages, come at lower cost and enhance convenience. The oral GLP-1 raceRight on the heels of oral semaglutide is a group of drugs led by Eli Lilly’s orforglipron, an oral medication that also targets GLP-1, which is a hormone implicated in insulin regulation, appetite and digestion. Drugmakers including Pfizer and Roche, as well as smaller companies like Structure Therapeutics, Terns Pharmaceuticals and Viking Therapeutics, also have oral weight-loss drugs in earlier stages of development, BMO research shows.

Persons: Jared Holz, ” Holz, ”, Jody Dushay, Dushay, ” Dushay, it’s, Rybelsus, Jorge Moreno, “, ” Moreno, Eli Lilly’s orforglipron, Lilly, Evan Seigerman, amycretin, who’ve, Dr, Sanjay Gupta, Holz, he’s, he’d Organizations: CNN, Harvard Medical School, Beth Israel Deaconess Medical, Novo Nordisk, US Food and Drug Administration, Yale School of Medicine, BMO Capital Markets, Pfizer, Roche, Therapeutics, Terns Pharmaceuticals, Viking Therapeutics, BMO, Nordisk, European Association for, Diabetes, Inversago Pharma, CNN Health Locations: Danish, Novo

☆ Op-ed: Here’s why a sale of Bausch + Lomb could lead to a windfall for Bausch Health investors
▼ + stars: | 2024-09-17 | by ( Kenneth Squire | ) www.cnbc.com time to read: +7 min

Bausch + Lomb parent company Bausch Health is spinning off the eye-care company with an upcoming IPO which will list on the New York Stock Exchange and TSX with the ticker symbol “BLCO”. This would greatly benefit BLCO stockholders, of which Bausch Health is the largest. As an 88% owner of BLCO, Bausch Health's value derived from such a sale would be $12.32 billion. Adding the value of the proceeds from BLCO sale, the Xifaxan cash flows and RemainCo yields a total value of $25.93 billion for Bausch Health. After subtracting 100% of the Bausch Health debt, that would yield an equity value of $10.49 billion or $28.19 per share.

Persons: Bausch, Scott Olson, Richard Mulligan, John Paulson, Brett Icahn, Steven Miller, Carl Icahn, BLCO, Goldman Sachs, Bausch Health's, Peers, InMode, Takeda, Gary Hu, Brent Saunders, Ken Squire Organizations: Bausch Health, New York Stock Exchange, TSX, U.S . Securities, Exchange, Financial Times, Cooper Companies, BLCO, Products, Takeda Pharmaceuticals, Ironwood Pharmaceuticals, Health, 13D Locations: CHICAGO , ILLINOIS, Chicago , Illinois, BLCO

☆ How I'm approaching the stock market after its wild reversal to start September
▼ + stars: | 2024-09-15 | by ( Jim Cramer | ) www.cnbc.com time to read: +7 min

The week before, Broadcom had allegedly disappointed, causing Nvidia , the inevitable key to this market, to continue its descent. Which brings me back to the initial concept of the big declining week followed by the big advancing week. A good week for Kamala Harris turns out to be a big week for Nextracker — and that's really it for now. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. If Jim has talked about a stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade.

Persons: Larry Ellison, Ellison, Cerner, Ellison's, Eaton, Jensen, Bing, Microsoft's Bing, underinvesting, Huang, Blackwell, Dupont, Kamala Harris, Nextracker, Jim Cramer's, Jim Cramer, Jim, Justin Sullivan Organizations: Nasdaq, Federal, Broadcom, Nvidia, Oracle, Marvell, Meta, Microsoft, Google, mightily, Street, Fed, Dreamforce, downer, Adobe, JPMorgan, Healthcare, pharma, Jim Cramer's Charitable, CNBC Locations: Silicon Valley, San Francisco

Search resuls for: "pharma"

25 mentions found